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Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its temporal ordering is poorly understood. We
aimed to determine the sequence in which grey matter regions become atrophic in multiple sclerosis and its association with
disability accumulation. In this longitudinal study, we included 1417 subjects: 253 with clinically isolated syndrome, 708 with
relapsing-remitting multiple sclerosis, 128 with secondary-progressive multiple sclerosis, 125 with primary-progressive multiple
sclerosis, and 203 healthy control subjects from seven European centres. Subjects underwent repeated MRI (total number of scans
3604); the mean follow-up for patients was 2.41 years (standard deviation = 1.97). Disability was scored using the Expanded
Disability Status Scale. We calculated the volume of brain grey matter regions and brainstem using an unbiased within-subject
template and used an established data-driven event-based model to determine the sequence of occurrence of atrophy and its
uncertainty. We assigned each subject to a specific event-based model stage, based on the number of their atrophic regions.
Linear mixed-effects models were used to explore associations between the rate of increase in event-based model stages, and T2
lesion load, disease-modifying treatments, comorbidity, disease duration and disability accumulation. The first regions to become
atrophic in patients with clinically isolated syndrome and relapse-onset multiple sclerosis were the posterior cingulate cortex and
precuneus, followed by the middle cingulate cortex, brainstem and thalamus. A similar sequence of atrophy was detected in
primary-progressive multiple sclerosis with the involvement of the thalamus, cuneus, precuneus, and pallidum, followed by the
brainstem and posterior cingulate cortex. The cerebellum, caudate and putamen showed early atrophy in relapse-onset multiple
sclerosis and late atrophy in primary-progressive multiple sclerosis. Patients with secondary-progressive multiple sclerosis showed
the highest event-based model stage (the highest number of atrophic regions, P50.001) at the study entry. All multiple sclerosis
phenotypes, but clinically isolated syndrome, showed a faster rate of increase in the event-based model stage than healthy controls.
T2 lesion load and disease duration in all patients were associated with increased event-based model stage, but no effects of disease-
modifying treatments and comorbidity on event-based model stage were observed. The annualized rate of event-based model stage
was associated with the disability accumulation in relapsing-remitting multiple sclerosis, independent of disease duration
(P50.0001). The data-driven staging of atrophy progression in a large multiple sclerosis sample demonstrates that grey matter
atrophy spreads to involve more regions over time. The sequence in which regions become atrophic is reasonably consistent across
multiple sclerosis phenotypes. The spread of atrophy was associated with disease duration and with disability accumulation over
time in relapsing-remitting multiple sclerosis.
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Introduction
Multiple sclerosis is an inflammatory demyelinating disease
of the CNS with a prominent neurodegenerative component.
Brain atrophy, as assessed by MRI, develops at a faster rate
in patients with multiple sclerosis than healthy control sub-
jects. Whole brain atrophy is the result of grey matter, and,
to a lesser extent, white matter atrophy (Fisher et al., 2008),
and is related to long-term disability in multiple sclerosis
(Fisniku et al., 2008; Filippi et al., 2013). Histology studies
have demonstrated that imaging-derived grey matter atrophy
reflects neurodegeneration (Filippi et al., 2012).
Grey matter atrophy is not uniform across the brain in
multiple sclerosis, and some regions are more susceptible to
atrophy than others (Steenwijk et al., 2016; Preziosa et al.,
2017). The limbic system, temporal cortex and deep grey
matter show rapid atrophy in patients with relapse-onset
multiple sclerosis (Audoin et al., 2010), while the cingulate
cortex shows early atrophy in primary-progressive multiple
sclerosis (Eshaghi et al., 2014). In our previous study using
the same large cohort of multiple sclerosis patients (Eshaghi
et al., 2018), we found that the deep grey matter showed
the fastest annual rate of tissue loss in relapsing-remitting
multiple sclerosis and progressive multiple sclerosis, and
that in the cortex the rate of atrophy accelerated in the
temporal regions in secondary-progressive multiple scler-
osis. However, it is unknown whether there is a consistent
and identifiable order in which atrophy progresses affecting
different areas over time. A key question is whether there is
an association between the sequential development of atro-
phy and disability accumulation.
One approach to investigate the sequence of atrophy pro-
gression is to use a probabilistic data-driven method, such as
an event-based model, which, as the name implies, identifies
the sequence of events at which a biomarker becomes abnor-
mal, using cross-sectional or longitudinal observations
(Fonteijn et al., 2012; Young et al., 2014). The event-based
model is an established method. It has given new insights into
the progression of Alzheimer’s disease in which the hippo-
campal atrophy is seen before the whole brain atrophy.
Similarly, in Huntington’s disease, the event-based model
has detected the earlier atrophy in the basal ganglia than
other regions (Fonteijn et al., 2012; Young et al., 2014).
In this study, we have introduced a novel validation tech-
nique for the event-based model and then used it to inves-
tigate the progression of brain atrophy as a sequence of
‘events’ at which grey matter regions become atrophic in
all phenotypes of multiple sclerosis. To define when the
volume of a region ceases to be normal and becomes atro-
phic, the event-based model does not rely on a priori
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thresholds but calculates the probability of atrophy based
on data-derived model distributions of normal and atrophic
regional volumes. Moreover, the event-based model con-
structs a subject staging system: it assigns each subject to
a stage that reflects how far through the sequence of regions
that subject shows lower than normal volumes—the higher
the stage, the higher the number of atrophic areas.
In this study, we built on the evidence that neurodegen-
eration in multiple sclerosis does not affect all the grey
matter regions equally (Haider et al., 2016; Eshaghi
et al., 2018) and those brain regions become atrophic in
a non-random manner (Rocca et al., 2010). We hypothe-
sized that: (i) there is a sequence in which grey matter re-
gions become atrophic; (ii) this sequence differs between
relapse- and progressive-onset multiple sclerosis pheno-
types; and (iii) the event-based model stage increases with
disease duration and disability worsening.
Materials and methods
Participants
This was a retrospective study of 1424 participants, studied
between 1996 and 2016 in seven European centres, which
were part of the Magnetic Resonance in Multiple Sclerosis
(MAGNIMS) Collaboration (www.magnims.eu). The same par-
ticipants were previously used to investigate the spatiotemporal
pattern of grey matter atrophy in multiple sclerosis (Eshaghi
et al., 2018). Subjects comprised healthy controls, patients
with the clinically isolated syndrome, relapsing-remitting mul-
tiple sclerosis, secondary-progressive multiple sclerosis and pri-
mary-progressive multiple sclerosis. Eligibility criteria included:
(i) a diagnosis of clinically isolated syndrome or multiple scler-
osis according to the 2010 McDonald Criteria (Polman et al.,
2011); (ii) healthy controls without history of neurological or
psychiatric disorders; (iii) the presence of at least two sequential
MRI scans, acquired with an identical protocol, including T1-
weighted MRI and T2-weighted/fluid attenuated inversion re-
covery (FLAIR) sequences; and (iv) a minimum interval of 6
months between scans. We requested that the Expanded
Disability Status Scale (EDSS) score at clinical follow-ups on
the eligible patients be made available (Kurtzke, 1983).
An additional group of age-matched healthy controls
(n = 29) was also obtained from the Parkinson’s Progression
Markers Initiative (PPMI) database (www.ppmi-info.org/data)
to match healthy controls’ age to that of patients.
Magnetic resonance scans were acquired under written con-
sent obtained from each participant independently in each
centre. The final protocol for this study was reviewed and
approved by the European MAGNIMS collaboration for the
analysis of pseudo-anonymized scans.
MRI data and analysis
We collected 3D T1-weighted scans, in addition to T2/FLAIR
imaging, from all centres except one. Details of the 13 different
MRI protocols are shown in Supplementary Table 1.
The aim of the image analysis was to extract the volume of
brain regions according to the Desikan-Killiany-Tourville
protocol (Klein and Tourville, 2012) [as explained in detail else-
where (Eshaghi et al., 2018)]. Briefly, the main steps were as
follows: after an N4-bias field correction (part of ANTs software,
version 4.1.9), which adjusted for the inhomogeneous intensity of
the T1-weighted scans (Tustison et al., 2010), we performed T1
lesion filling (Battaglini et al., 2012) to improve the accuracy of
the segmentation with the co-registered T2 lesion masks. We then
created an unbiased, within-subject template, and linearly trans-
formed all the subject-specific T1 scans to this symmetric space,
using Freesurfer version 5.3 (Reuter et al., 2010, 2012; Reuter
and Fischl, 2011). In the symmetric space, we segmented the T1
scans in the grey matter, white matter and CSF using the
Geodesic Information Flows software (part of NiftySeg, http://
cmictig.cs.ucl.ac.uk/niftyweb/) (Cardoso et al., 2015). Finally, we
calculated regional volumes in the cortex and deep grey matter
(the volumes of respective regions were averaged between the left
and right hemisphere), the brainstem, white matter, cerebellum
and lateral ventricles, according to the Desikan-Killiany-Tourville
protocol (http://braincolor.mindboggle.info/index.html) (Klein and
Tourville, 2012).
The event-based model
We used the event-based model, as described previously
(Fonteijn et al., 2011, 2012; Young et al., 2014), to estimate
the most likely sequence in which selected regions become
atrophic over time (see below for details on region selection).
We also repeated the same analysis using all brain regions to
test the dependence of our findings on the region selection.
The event-based model assumes that a population of patients
represents the whole trajectory of disease progression (Fonteijn
et al., 2011) and reconciles cross-sectional or short-term lon-
gitudinal data into a picture of the entire disease course. We,
therefore, created separate event-based models for (i) relapse-
onset patients (the clinically isolated syndrome, relapsing-
remitting, and secondary-progressive multiple sclerosis);
(ii) progressive-onset (or primary-progressive) patients; and
(iii) all clinical phenotypes together (to develop a unique sta-
ging system for the whole cohort). We used the sequence esti-
mated by the latter event-based model to stage patients by
assigning them the most probable stage along the sequence.
The main steps of the event-based model include (Fig. 1):
(i) model input, which consists of the adjustment of regional
volumes for effects of nuisance variables and selection of regions;
(ii) model fitting; and (iii) a cross-validation. For the last step, we
used a novel cross-validation method, used here within the event-
based model for the first time, while steps (i) and (ii) have not
changed since the original event-based model implementations
(Fonteijn et al., 2011; Young et al., 2014). Model input used
all multiple sclerosis patients. Model fitting and cross-validation
were repeated three times using (i) relapse-onset and the clinically
isolated patients together; (ii) primary-progressive multiple scler-
osis; and (iii) the whole cohort of patients.
Model input
We adjusted the regional volumes for the total intracranial
volume, age at study entry, gender, scanner magnetic field and
MRI protocol. Since some centres provided data from more
than one imaging protocol (Supplementary Table 1), we ad-
justed for imaging protocol and magnetic field (instead of
‘centre’). We constructed a regression model for each region
separately, entering the volume as the dependent variable and
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the remaining variables as predictors. We extracted the amount
of each regional volume that remained unexplained in the re-
gression (residual of the fit). Subsequently, we selected the re-
gions whose adjusted volumes at the study entry showed a
significant difference between all multiple sclerosis patients and
healthy controls, with a Bonferroni corrected P50.01 (uncor-
rected P50.0001). We used these regions in the subsequent
analyses. We then repeated the analysis using all the segmented
regions of the Desikan-Killiany-Tourville atlas for the following
reasons: (i) to test whether the sequence in which brain regions
become atrophic was not influenced by restricting the analysis
only to the regions that showed a lower volume in patients than
controls; and (ii) to detect potential subtle early changes that
might not have survived multiple-comparison correction.
Model fitting
The event-based model considers an ‘event’ to have occurred
when a biomarker, here regional volume, has abnormal value
(‘atrophy’) in comparison with the expected values measured in
healthy controls. The model then estimates the sequence
S = S(1), S(2), . . ., S(l) in which regions become atrophic,
where S(1) is the first region, and S(l) is the last to become
atrophic. The model assumes that all patients go through the
same sequence as they progress. The estimation procedure first
fits a mixture of two Gaussians to regional volumes, with one of
the components fixed to be identical to the healthy distribution;
the other component provides the model for the ‘abnormal’
distribution. This provides probabilistic models for normal
and abnormal volumes from which we can calculate the likeli-
hood of atrophy P xijjEi
 
for the region i of the scan j, i.e. the
probability density function (PDF) estimated at xij from the ab-
normal component of the mixture model. The likelihood that
region i has no atrophy or P xijj:Ei
 
, is the PDF of the normal
component of the mixture-model estimated at xij Fig. 1B(i)].
To search for the most likely sequence, we used a greedy
ascent search (Fonteijn et al., 2012; Young et al., 2014) that
Figure 1 The event-based model steps to estimate the most likely sequence of atrophy progression. The three steps are:
(A) adjusting for nuisance variables, and region selection; (B) calculating the best-fit probability distributions for normal and atrophic brain
regions; searching for the most likely sequence; and (C) quantifying the uncertainty with cross-validation. [B(i)] The distribution of the volume in
an example region in healthy controls and patients and the corresponding mixture model. (ii) The steps for greedy ascent search. (iii) A matrix
showing a sequence of atrophy progression on the y-axis, and the position in the sequence of each region ranging from 1 to the total number of
regions on the x-axis. The intensity of each matrix entry corresponds to the proportion of Markov Chain Monte Carlo samples of the posterior
distribution where a certain region of y-axis appears at the respective stage of x-axis.
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started at 10 different random sequences and was iterated by
randomly flipping sequences for 1000 times. The final sequence
was selected when 10 different initial sequences converged to a
similar likelihood after 1000 iterations. Within each iteration
new (flipped) sequences [Fig. 1B(ii)] were accepted only if they
increased the likelihood, which is defined as:














where X is the data matrix, S is the sequence of atrophy
events, J is the number of scans, l is the number of regions,
and P(k) is the prior probability of being at stage k, which
means E1, . . ., Ek have occurred, and Ek + 1, . . ., El have not
occurred. We used a uniform distribution for prior probabil-
ities, which assumes equal prior-probability for all possible
stages; all sequences are equally likely a priori. The software
and codes for the event-based model are freely available at
https://github.com/ucl-mig/ebm.
Cross-validation of atrophy sequence
After estimating the most likely sequence, the uncertainty in
the position of each region in the sequence was estimated using
cross-validation and Markov Chain Monte Carlo. We divided
the dataset (including baseline and follow-up visits) into 10
equally-sized folds (cross-validation folds) and repeated the se-
quence estimation 10 times. During each iteration, we used
nine folds to fit the mixture-models (as explained above) and
estimated the most-likely sequence. We kept one fold out as
the test fold to assign the event-based model stages (explained
below). Within each iteration, we used Markov Chain Monte
Carlo to sample from the posterior distribution on the se-
quence given the nine-fold training data (Fonteijn et al.,
2012; Young et al., 2014). We then aggregated Markov
Chain Monte Carlo samples from the 10 iterations of cross-
validation (10 000 samples from each fold) to calculate uncer-
tainty across cross-validation folds. Finally, we used these
100 000 sampled sequences to plot the positional variance dia-
gram (as in Fonteijn et al., 2012; Young et al., 2014), which
shows on the y-axis the sequence with the highest likelihood,
and the x-axis enumerates the number of sequence positions
(or the event-based model stages). The intensities of the matrix
entries correspond to the proportion of Markov Chain Monte
Carlo samples in which the corresponding region (y-axis) ap-
pears at the respective stage (x-axis). Therefore, if there were
no uncertainty, i.e. all Markov Chain Monte Carlo samples in
all folds find the same sequence, the matrix would be black on
the diagonal and white everywhere else; non-white off-diag-
onal and non-black diagonal elements indicate uncertainty in
the position of the corresponding region in the sequence.
Staging individual subjects and
associations with white matter lesion
load, disease duration and disability
We used the most likely sequence of atrophy progression from
the whole patient cohort-based event-based model to obtain
the event-based model stage for each scan j, which is the







This assigned each subject an event-based model stage between
1 and the number of regions, l, at each visit (Fig. 1).
We used a nested linear mixed-effects model to investigate
the association between the event-based model stage (depend-
ent variable) and T2 lesion load (independent variable), in
which time was nested in subject as the random-effect (to
adjust for repeated measures). Similarly, we used a nested
mixed-effects regression model to explore the association be-
tween the event-based model stage (dependent variable) and
disease duration (independent variable), in which disease dur-
ation was nested in subject as the random effect.
For those clinical phenotypes that showed a significant
change in the event-based model stage over time (relapsing-
remitting, secondary-progressive and primary-progressive mul-
tiple sclerosis), we investigated whether longitudinal EDSS
changes could be predicted by event-based model changes in-
dependent of disease duration. We divided the changes in the
EDSS and event-based model by the number of years from the
study entry and performed a linear regression analysis where
the annualized EDSS change was the outcome variable.
Annualized event-based model stage change and disease dur-
ation at the study entry were the predictor variables. Since
both the event-based model stage and EDSS are ordinal vari-
ables, we used ordinal regression analyses to confirm the re-
sults of the linear regressions but presented the results of linear
models (as they did not materially differ).
Confounding effects of disease-modifying treatments
and comorbidities
To test whether disease-modifying treatments could affect the
event-based model stages at baseline and over time, we
used similar mixed-effects models (as above) in which the
event-based model stage was the outcome variable; time, dis-
ease-modifying treatment (as a categorical variable), and their
interaction were the fixed-effect variables. Random effects were
the same as explained above. We performed additional analyses
to assess the effects of comorbidities on the event-based model
stages, which are reported in the Supplementary material.
Results
Subject characteristics
Imaging data from 1424 subjects were analysed; three sub-
jects’ scans were excluded because of motion artefacts and
four because of poor registration due to missing imaging
header information. Therefore, data from 1417 subjects
were included in the final modelling: 1214 patients (253
clinically isolated syndrome, 708 relapsing-remitting, 128
secondary-progressive, and 125 primary-progressive mul-
tiple sclerosis), and 203 healthy controls. The average
[ standard deviation (SD)] length of follow-up for pa-
tients was 2.43 years (1.97) and for healthy controls
was 1.83 years (1.77). In total, we analysed 3604 T1-
weighted scans [mean number of scans per patient was
2.54 (SD = 1.04)] (Table 1).
Sequence of atrophy progression
At baseline, 24 regions showed a smaller volume in mul-
tiple sclerosis than healthy controls (Bonferroni corrected
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P50.01). They included the deep grey matter regions and
the posterior cortices (including the precuneus and the pos-
terior cingulate cortex), several regions in the temporal
lobe, the precentral cortex, and the brainstem (see Fig. 2
for the full list).
When we estimated the sequence in which these 24
regions become atrophic in patients with relapse-onset
multiple sclerosis (i.e. relapsing-remitting and secondary-
progressive) and the clinically isolated syndrome, the first
regions were the posterior cingulate cortex and precuneus,
followed by the middle cingulate cortex, brainstem, and
thalamus (Fig. 3A and D); the last regions to become atro-
phic were the pallidum and medial precentral gyrus.
In patients with primary-progressive multiple sclerosis,
among the 24 selected regions, the first ones to show
atrophy were the thalamus, cuneus and precuneus, and
pallidum, followed by the brainstem, precentral gyrus,
and posterior cingulate cortex (Fig. 3B and D); the last
regions to become atrophic were the frontal operculum
and middle temporal gyrus.
When the event-based model was used to estimate the se-
quence of atrophy progression of the selected 24 regions in
all patients together, additional regions were detected as
showing early atrophy, such as the insula, accumbens and
caudate (Fig. 3C). The likelihood of the 10 randomly chosen
sequences (log-likelihood range: 149 000 to 117 000) con-
verged to a similar range (log-likelihood range: 1 000 000
to 99 000) after 1000 iterations (Supplementary Fig. 1). For
other event-based models, the likelihoods converged to a
similar range (results are not shown).
Figure 2 Comparisons of regional volumes between groups. Box plots at y-axis show z-scores of the corresponding region shown at
x-axis. Lower and upper hinges of each boxplot correspond to 25th and 75th percentiles of data. We selected 24 regions that showed significant
difference (P50.01 corrected) between all patients with multiple sclerosis and healthy controls at baseline visit. CIS = clinically isolated syndrome;
HC = healthy control; PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary
progressive multiple sclerosis.













n (females, n) 203 (112) 253 (171) 836 (548) 125 (55)
Age (SD) 38.7  10.5 33  8 39.7  9.8 48.5  10.1
Disease duration (SD) – 0.4  1.4 8.06  8.03 6.8  5.9
Median EDSS (range) – 1 (0–4.5) 2 (0–9) 5 (2–8)
Per cent (n) of patients receiving disease-modifying treatments – 20 (52) 47 (397) 6 (8)
Baseline median white matter T2 lesion load (ml) (1st–3rd quartile) – 2.97 (1.01–5.04) 5.04 (2.05–11.79)
b 9.38 (2.69–22.02)
aRelapse-onset group includes both the relapsing-remitting and secondary-progressive patients.
bBaseline median T2 lesion load were the following: for relapsing-remitting = 5.05 (2.05–11.79) and secondary-progressive multiple sclerosis = 11.04 (3.18–23.14).
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When all the remaining regions were included additional
regions were identified. In primary-progressive multiple
sclerosis, they were the transverse temporal gyrus, cerebral
white matter, post-central gyrus and middle frontal gyrus
(Fig. 4 and Supplementary Figs 2 and 3). In the relapse-
onset group, these regions were the superior frontal gyrus,
inferior frontal gyrus, and middle frontal gyrus.
When we qualitatively compared the clinically isolated
syndrome and relapse-onset multiple sclerosis patients
with primary-progressive multiple sclerosis, across all re-
gions, the cerebellum, caudate and putamen showed a dif-
ferential pattern of atrophy, with early atrophy in patients
with relapse-onset disease and late atrophy in primary pro-
gressive multiple sclerosis (Fig. 4).
Event-based model staging of
individual subjects
Patients with clinically isolated syndrome and relapse-onset
multiple sclerosis and primary-progressive multiple sclerosis
had significantly higher event-based model stages at base-
line than healthy controls [average intercept ( standard
error (SE)] of the event-based model stage for healthy con-
trol subjects = 8.02 (0.59), relapse-onset = 12.39 (0.66),
primary-progressive multiple sclerosis = 12.22 (0.35),
P50.05]; when looking at each clinical phenotype, patients
with secondary-progressive multiple sclerosis had the high-
est event-based model stage at the study entry [14.73
Figure 3 Sequences of atrophy progression and patient staging. The positional variance diagrams for (A) relapse-onset multiple
sclerosis, (B) primary-progressive multiple sclerosis (PPMS) and (C) merged cohort of patients, show the most likely sequences of atrophy and
their associated uncertainty. In A–C, the y-axis shows the most likely sequence of atrophy progression, and the x-axis shows the sequence
position ranging from one to the total number of regions. The intensity of each rectangle corresponds to the proportion of Markov Chain Monte
Carlo samples of the posterior distribution where a certain region of y-axis appears at the respective stage of the x-axis. (D) The evolution of the
event-based model (EBM) stage (or atrophy progression staging) over time in clinically isolated syndrome and relapse-onset multiple sclerosis
together and primary-progressive multiple sclerosis. Each line in D is the prediction of the mixed-effects model whose ribbon shows standard
error of the prediction. MS = multiple sclerosis.
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(0.93), all P-values50.001], followed by relapsing-remit-
ting [12.60 (0.67)], primary-progressive multiple sclerosis
[12.22 (0.35)], clinically isolated syndrome [8.12
(0.76)], and healthy controls [8.02 (0.59)]. The
annual rate of change (or slope) in the event-based model
stage over time was significant (null-hypothesis = zero
slope) for secondary-progressive multiple sclerosis [average
slope (SE) = 1.02 (0.41)], primary-progressive [0.52
(0.34)], and relapsing-remitting multiple sclerosis [0.37
(0.26)], but not for clinically isolated syndrome [0.19
(0.33)] and healthy controls [0.10 (0.24)]. The rate
of change, although nominally higher in secondary progres-
sive multiple sclerosis, was not significantly different be-
tween clinical phenotypes.
Association of the event-based model
stages with white matter T2 lesion
load, disease duration and disability
accumulation
At baseline, the highest T2 lesion load was observed in
secondary-progressive multiple sclerosis, followed by pri-
mary-progressive multiple sclerosis (Table 1). There was a
significant association between the event-based model stage
and white matter lesion load (standardized  = 0.11,
P50.001) in all patients, which means for every standard
deviation (15.31 ml) increase in the lesion load there was a
0.11 SD (1.06 unit) increase in the event-based model stage.
However, there was no association between the rate of
change in the event-based model stage over time and the
rate of increase in lesion load.
There was a significant association between the rate of
increase in the event-based model stages and disease dur-
ation in all patients with multiple sclerosis ( = 0.21,
SE = 0.03, P50.001) using all available time points. This
means that for every increase of one event-based model
stage, disease duration increased by 4.76 years.
At the baseline visit, there was no significant association
between the event-based model stage and the EDSS in any
clinical phenotype. Over time there was a significant in-
crease in the EDSS in both relapse-onset multiple scler-
osis/clinically isolated syndrome and primary-progressive
multiple sclerosis patients (an increase of 0.07 and 0.2
per year, respectively, P50.01). There was a significant
association (independent of disease duration) between the
annualized event-based model stage and the annualized
EDSS changes in relapsing-remitting multiple sclerosis
(beta = 0.03, P50.0001), but not in secondary-progressive
and primary-progressive multiple sclerosis. This means that
assuming a linear relationship between the EDSS and the
event-based model stage, for every unit increase in the
annual rate of the event-based model stage there is 0.03
increase in the annual rate of EDSS worsening.
Figure 4 Regional atrophy and its sequence of progression in all grey matter regions plus brainstem in relapse-onset disease
and primary progressive multiple sclerosis. The probability of atrophy in each region was calculated from the positional variance diagrams
and colour coded, so that brighter colour corresponded to a higher probability of seeing atrophy in the corresponding event-based model stage.
MS = multiple sclerosis.
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Disease-modifying treatments and
comorbidity did not affect the event-
based model stages
Information on whether or not a patient was receiving a
disease-modifying treatment was available for 98% of pa-
tients (n = 1179) at baseline. Of these, 38% (n = 457) were
receiving a disease-modifying therapy; 47% of patients
with relapse-onset multiple sclerosis, 20% of patients
with clinically isolated syndrome and 6% of patients with
primary-progressive multiple sclerosis were on treatment
(Table 1). Information on the type of disease-modifying
treatment was available for 56% of these patients
(n = 255), of whom 86% (n = 220) were receiving either
interferons or glatiramer acetate, and the remaining 14%
(n = 35) of patients were on other treatments, including
natalizumab, fingolimod, mitoxantrone, and teriflunomide.
Linear mixed-effects models showed that at baseline (esti-
mated average  SE) the event-based model stage was not
significantly different (P = 0.21) between patients who were
on disease-modifying treatments (12.63  0.32) compared
to those who were not (11.98  0.52). The same model
showed that the annual rate of change (estimated
range  SE) in the event-based model stage was not signifi-
cantly different (P = 0.45) between patients who were on
disease-modifying treatments (0.53  0.17) and those who
were not (0.39  0.10).
Similarly, we found negative results on whether the
event-based model stage and its rate of change over time
differed between patients with and without comorbidity
(Supplementary material).
Discussion
In this study, we used a data-driven method to determine
the most likely sequence in which brain regions become
atrophic in multiple sclerosis. This sequence is consistent
in key regions across multiple sclerosis phenotypes: the pos-
terior cingulate cortex, precuneus, and thalamus were
among the earliest regions to become atrophic in both re-
lapse-onset phenotypes and primary-progressive multiple
sclerosis. The event-based model staging system was
applied to individual patients, and the rate of increase in
the event-based model stage was associated with the disease
duration in all multiple sclerosis phenotypes and with the
EDSS in patients with relapsing-remitting multiple sclerosis
independent of the disease duration. These results provide
insights into the mechanisms of disease worsening in mul-
tiple sclerosis.
The order of atrophy progression in the event-based
model for most regions was similar between primary-pro-
gressive multiple sclerosis and the clinically isolated syn-
drome/relapse-onset multiple sclerosis. This may support
the evidence from histological studies that the pathological
processes are regionally consistent between early relapsing-
remitting and progressive multiple sclerosis (Mahad et al.,
2015). Our results showed that areas with an early atrophy
were the posterior cingulate cortex, precuneus, thalamus
and brainstem in both groups, thereby extending the results
of previous studies, which have limited their investigation
to specific multiple sclerosis subtypes (Gilmore et al., 2009;
Audoin et al., 2010; Calabrese et al., 2015b; Steenwijk
et al., 2016). When all patients were included together,
the insula, accumbens and caudate were predicted as
becoming atrophic early on.
The cingulate cortex and insula have extensive connec-
tions with other regions. Possible factors for their early
atrophy, therefore, can include disconnection secondary to
white matter lesions, inflammation, and more specifically
meningeal inflammation. We, therefore, calculated white
matter T2 lesion volumes and showed that there was an
association between increasing lesion load at baseline and
the event-based model stages. Since assessing meningeal in-
flammation is challenging in vivo we can just speculate that
structures in cortical invaginations can be exposed to men-
ingeal inflammation, cortical demyelination, and neurode-
generation (Gilmore et al., 2009; Howell et al., 2011;
Haider et al., 2016). The cingulate cortex and precuneus
are part of a network of active regions during rest (the
default mode network) (Raichle, 2015). These regions are
interconnected with other areas, have the highest energy
consumption in the brain, and are affected by multiple
sclerosis and other neurodegenerative disorders (Bonavita
et al., 2011; Raichle, 2015). In multiple sclerosis, neurons
with demyelinated axons consume more energy to adapt to
demyelination, which creates a micro-environment similar
to that of hypoxia (‘virtual hypoxia’) (Trapp and Stys,
2009). Neurons that survive in a state of persistent virtual
hypoxia are more vulnerable to degeneration (Zhang and
Raichle, 2010), and this may explain the higher vulnerabil-
ity of the cingulate and precuneus cortex to atrophy.
Other regions that showed early atrophy were the thal-
amus and the brainstem in both relapse-onset multiple
sclerosis and primary-progressive multiple sclerosis. In our
previous study, we found that the deep grey matter showed
the fastest rate of atrophy over time, while brainstem had
the highest atrophy (the lowest volume) at study entry, but
its atrophy progressed at a slower rate than that occurring
in other regions (Eshaghi et al., 2018). This may suggest
that during early stages of multiple sclerosis, the rate of
atrophy in the brainstem is higher than later stages, while
the rate of atrophy in the thalamus remains high through-
out the disease course. The brainstem is in close contact
with the spinal cord, whose atrophy is seen from early
stages of multiple sclerosis independent of the cortex or
deep grey matter (Biberacher et al., 2015; Ruggieri et al.,
2015).
Several mechanisms may underlie neurodegeneration in
the deep grey matter, including mitochondrial failure, iron
deposition, retrograde degeneration through white matter
lesions, and meningeal inflammation (for structures closer
to CSF) (Calabrese et al., 2015a; Bodini et al., 2016;
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Haider et al., 2016; Pardini et al., 2016). Network over-
load and collapse, similar to the cingulate and precuneus
cortex, could also explain preferential atrophy of the deep
grey matter in multiple sclerosis (Minagar et al., 2013).
There were a few regions showing a differential pattern
of atrophy between relapse- and progressive-onset pheno-
types. The cerebellum, caudate and putamen were predicted
to have early atrophy in relapse-onset disease and late at-
rophy in primary-progressive multiple sclerosis. In the cere-
bellum, this different behaviour can be explained by a more
inflammatory phenotype of patients with relapse-onset mul-
tiple sclerosis. In patients with multiple sclerosis, more than
any other brain region, demyelination is seen in the cere-
bellar grey matter, which is five times more than the white
matter demyelination (Gilmore et al., 2009). This may be a
consequence of overlying meningeal inflammation in the
deep folia, which accommodate a static inflammatory
milieu (such as cytokines, and immunoglobulins)
(Kutzelnigg et al., 2007; Howell et al., 2011). Therefore,
in the cerebellum, overlying inflammation may play a role
and amplify other pathological mechanisms, such as retro-
grade neurodegeneration secondary to white matter lesions
(Kutzelnigg et al., 2007; Gilmore et al., 2009; Howell et al.,
2011). Thus, the cerebellum could be susceptible to inflam-
matory damage from the CSF. Previous studies have re-
ported in relapse-onset multiple sclerosis, but not
primary-progressive multiple sclerosis, tertiary lymphatic
follicles in cortical invaginations, which may suggest a
more inflammatory CSF milieu than primary-progressive
multiple sclerosis (Kutzelnigg et al., 2007; Choi et al.,
2012). This could explain earlier atrophy of the cerebellar
grey matter in people with relapse onset disease, while in
primary-progressive multiple sclerosis, neurodegeneration
in a less inflammatory CSF milieu might cause a gradual
progression of atrophy (Choi et al., 2012; Mahad et al.,
2015). However, this is speculative, and it remains unclear
whether meningeal inflammation has a causative effect on
demyelination and neurodegeneration.
The caudate and putamen, which are histologically simi-
lar, constitute a structure that is known as the neostriatum.
A previous histopathological study has shown that the
greatest extent of demyelination and lesions in the deep
grey matter can be seen in the caudate even in early mul-
tiple sclerosis, although the pattern was not different be-
tween multiple sclerosis phenotypes (Haider et al., 2014).
Moreover, the putamen receives significant inputs from the
motor cortex and the caudate from the association cortices.
Therefore, we could speculate that retrograde neurodegen-
eration secondary to a higher lesion load in relapse-onset
disease (compared to primary-progressive multiple sclerosis)
may perform as an additive factor on demyelination to
explain the higher vulnerability of these structures.
We extended our analysis from regions that showed sig-
nificant atrophy at baseline to the all segmented areas to
test the dependence of our findings to region selection.
Another reason was to explore early, but subtle changes
in brain regions, which might have been missed by just
looking at a snapshot at the study entry to choose specific
areas whose adjusted volumes showed a significant differ-
ence between all multiple sclerosis patients and healthy con-
trols, based on stringent multiple-comparison correction.
For example, a brain region may show mild volume loss
earlier than another part with a greater (but later) volume
loss through the course of multiple sclerosis. Whole brain
event-based model analysis predicted an early involvement
of the posterior cortices (posterior cingulate and precuneus)
along with the brainstem. New additional regions in the
whole brain event-based model were also identified as
showing atrophy at an early stage, including the superior,
middle, and inferior frontal gyri in relapse-onset pheno-
types, and the transverse temporal gyrus, white matter,
and post-central gyrus in primary-progressive multiple scler-
osis. These findings suggest that the changes in these struc-
tures may happen early, but with a lower intensity than
other regions that were selected initially (24 areas).
This study was not designed to investigate the effects of
disease-modifying drugs and comorbidities on the atrophy
stages. However, it does study the sequence of regional
atrophy in the presence of these confounders. There were
no significant differences at baseline or during the follow-
up in the event-based model stages of patients who were
receiving disease-modifying treatments and those who were
not, extending our previous results in the same group of
patients which demonstrated, using a different imaging
analysis method, that the rates of atrophy in neuroanatom-
ical regions were not confounded by disease-modifying
treatments (Eshaghi et al., 2018). Most of the patients
were receiving the injectable first-line therapies (interferon
beta and glatiramer acetate), whose effects on atrophy rates
are weak (Filippi et al., 2004; Cohen et al., 2010).
Although the information on comorbidities was only avail-
able for about a third of patients, we found that patients
with at least one comorbidity were older at baseline than
those without. This is in line with the literature showing
that comorbidities are prevalent in patients with multiple
sclerosis and increase with age (Marrie and Horwitz, 2010;
Geraldes et al., 2017). There was no significant effect of
comorbidity on event-based model stage at baseline or its
rate of change during the follow-up. One reason that age
influenced the frequency of comorbidities, but not the
number of atrophic regions, was that we had regressed
out the effects of age on the regional volumes. Therefore,
we conclude that disease-modifying treatments and comor-
bidity did not significantly influence our findings.
The event-based model has a potential for clinical use as it
does not rely on time and can be applied to individual
(cross-sectional) brain scans. To have a unique staging
system across all clinical phenotypes, we created an event-
based model from the whole patient cohort. We showed
that patients with secondary-progressive multiple sclerosis
had the highest event-based model stage—or the highest
number of atrophic regions—at the study entry. This, in
line with previous studies, suggests that secondary-progres-
sive multiple sclerosis has more advanced neurodegeneration
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across multiple sclerosis phenotypes (Ceccarelli et al., 2008).
When we performed the event-based model staging using
follow-up scans of patients and healthy controls, we
found a significant increase in event-based model stages in
all multiple sclerosis phenotypes, but not in the clinically
isolated syndrome or healthy controls (although the baseline
event-based model stage was nominally higher in the clinic-
ally isolated syndrome than healthy controls). The clinical
relevance of the event-based model was confirmed by a
significant association between stages and EDSS in relap-
sing-remitting multiple sclerosis, after adjusting for disease
duration. Therefore, the sequential pattern of atrophy may
explain disease worsening in relapsing-remitting multiple
sclerosis. We did not find the same association between
the changes in event-based model stages and EDSS in
other patient groups. However, patients with secondary-
progressive multiple sclerosis had the highest event-based
model stages at the study entry and the highest (nominal)
rate of increase in the event-based model stage.
Although this is a retrospective and multi-centre study,
we have adjusted for the effects of MRI protocol and scan-
ner magnetic field, and, as reported before on this dataset
(Eshaghi et al., 2018), the effect of multiple sclerosis pheno-
types on regional measures was higher than that from these
variables. A possible limitation is that the event-based
model assumes that all brain regions eventually become
abnormal (all regions show atrophy at the last stage).
Therefore, an implicit assumption is that patients with re-
lapse-onset disease (the clinically isolated syndrome, relap-
sing-remitting, and secondary-progressive multiple sclerosis)
represent the whole continuum of progression when ana-
lysed separately; future implementations of this model
could remove this assumption. We used the EDSS as the
clinical outcome, but both the EDSS and event-based model
provide measures that are ordinal, and may not have a
uniform interpretation. Therefore, the coefficients of asso-
ciations should be interpreted relatively (e.g. to compare
clinical groups) rather than absolutely.
We showed that the sequence of atrophy progression in
relapse-onset disease and primary-progressive multiple
sclerosis are similar in many key regions, while the cerebel-
lum, caudate and putamen show an earlier atrophy in re-
lapse-onset multiple sclerosis than primary-progressive
multiple sclerosis, perhaps due to a more inflammatory
milieu. The sequence of atrophy progression can be used
to score patients during multiple sclerosis automatically.
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d’Hebron, Universitat Autònoma de Barcelona, Barcelona,
Spain. Christian Enzinger: Department of Neurology,
Medical University of Graz, Graz, Austria Frederik
Barkhof: Queen Square Multiple Sclerosis Centre, UCL
Institute of Neurology, University College London,
London, UK. Olga Ciccarelli: Queen Square Multiple
Sclerosis Centre, UCL Institute of Neurology, University
College London, London, UK. Massimo Filippi:
Neuroimaging Research Unit, Institute of Experimental
Neurology, Division of Neuroscience, San Raffaele
Scientific Institute, Vita-Salute San Raffaele University,
Milan, Italy. Nicola De Stefano: Department of Medicine,
Surgery and Neuroscience, University of Siena, Siena, Italy.
Ludwig Kappos: Department of Neurology, University
Hospital, Kantonsspital, Basel, Switzerland. Jette
Frederiksen: The multiple sclerosis Clinic, Department of
Neurology, University of Copenhagen, Glostrup Hospital,
Denmark. Jaqueline Palace: Centre for Functional Magnetic
Resonance Imaging of the Brain, University of Oxford, UK.
Maria A Rocca: Neuroimaging Research Unit, Institute of
Experimental Neurology, Division of Neuroscience, San
Raffaele Scientific Institute, Vita-Salute San Raffaele
University, Milan, Italy. Jaume Sastre-Garriga:
Department of Neurology/Neuroimmunology, Multiple
Sclerosis Centre of Catalonia (CEMCAT), Hospital
Universitari Vall d’Hebron, Universitat Autònoma de
Barcelona, Barcelona, Spain. Hugo Vrenken: Department
of Radiology and Nuclear Medicine, multiple sclerosis
Center Amsterdam, Amsterdam, The Netherlands. Tarek
Yousry: NMR Research Unit, Institute of Neurology,
University College London, London, UK. Claudio
Gasperini: Department of Neurology and Psychiatry,
University of Rome Sapienza, Rome, Italy.
References
Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny
S, et al. Atrophy mainly affects the limbic system and the deep grey
matter at the first stage of multiple sclerosis. J Neurol Neurosurg
Psychiatry 2010; 81: 690–5.
Battaglini M, Jenkinson M, De Stefano N. Evaluating and reducing the
impact of white matter lesions on brain volume measurements. Hum
Brain Mapp 2012; 33: 2062–71.
Biberacher V, Boucard CC, Schmidt P, Engl C, Buck D, Berthele A,
et al. Atrophy and structural variability of the upper cervical cord in
early multiple sclerosis. Mult Scler 2015; 21: 875–84.
Bodini B, Chard D, Altmann DR, Tozer D, Miller DH, Thompson AJ,
et al. White and gray matter damage in primary progressive MS: the
chicken or the egg? Neurology 2016; 86: 170–6.
Bonavita S, Gallo A, Sacco R, Corte MD, Bisecco A, Docimo R, et al.
Distributed changes in default-mode resting-state connectivity in
multiple sclerosis. Mult Scler 2011; 17: 411–22.
Calabrese M, Magliozzi R, Ciccarelli O, Geurts JJG, Reynolds R,
Martin R. Exploring the origins of grey matter damage in multiple
sclerosis. Nat Rev Neurosci 2015a; 16: 147–58.
Calabrese M, Reynolds R, Magliozzi R, Castellaro M, Morra A,
Scalfari A, et al. Regional distribution and evolution of gray
matter damage in different populations of multiple sclerosis patients.
PloS One 2015b; 10: e0135428.
1676 | BRAIN 2018: 141; 1665–1677 A. Eshaghi et al.
Cardoso MJ, Modat M, Wolz R, Melbourne A, Cash D, Rueckert D,
et al. Geodesic information flows: spatially-variant graphs and their
application to segmentation and fusion. IEEE Trans Med Imaging
2015; 34: 1976–88.
Ceccarelli A, Rocca MA, Pagani E, Colombo B, Martinelli V, Comi G,
et al. A voxel-based morphometry study of grey matter loss in MS
patients with different clinical phenotypes. NeuroImage 2008; 42:
315–22.
Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro
PA, et al. Meningeal inflammation plays a role in the pathology of
primary progressive multiple sclerosis. Brain 2012; 135: 2925–37.
Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban
X, et al. Oral fingolimod or intramuscular interferon for relapsing
multiple sclerosis. N Engl J Med 2010; 362: 402–15.
Eshaghi A, Bodini B, Ridgway GR, Garcia-Lorenzo D, Tozer DJ,
Sahraian MA, et al. Temporal and spatial evolution of grey matter
atrophy in primary progressive multiple sclerosis. Neuroimage 2014;
86: 257–64.
Eshaghi A, Prados F, Brownlee W, Altmann DR, Tur C, Cardoso MJ,
et al. Deep gray matter volume loss drives disability worsening in
multiple sclerosis. Ann Neurol 2018; 83: 210–22.
Filippi M, Preziosa P, Copetti M, Riccitelli G, Horsfield MA,
Martinelli V, et al. Gray matter damage predicts the accumulation
of disability 13 years later in MS. Neurology 2013; 81: 1759–67.
Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, et al.
Association between pathological and MRI findings in multiple
sclerosis. Lancet Neurol 2012; 11: 349–60.
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S,
et al. Interferon beta-1a for brain tissue loss in patients at presenta-
tion with syndromes suggestive of multiple sclerosis: a randomised,
double-blind, placebo-controlled trial. Lancet 2004; 364: 1489–96.
Fisher E, Lee J-C, Nakamura K, Rudick RA. Gray matter atrophy in
multiple sclerosis: a longitudinal study. Ann Neurol 2008; 64: 255–
65.
Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR,
Miszkiel KA, et al. Gray matter atrophy is related to long-term
disability in multiple sclerosis: GM Atrophy and Disability in MS.
Ann Neurol 2008; 64: 247–54.
Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M,
Ourselin S, et al. An event-based disease progression model and
its application to familial Alzheimer’s disease. Inf Process Med
Imaging 2011; 22: 748–59.
Fonteijn HM, Modat M, Clarkson MJ, Barnes J, Lehmann M, Hobbs
NZ, et al. An event-based model for disease progression and its
application in familial Alzheimer’s disease and Huntington’s disease.
NeuroImage 2012; 60: 1880–9.
Geraldes R, Esiri MM, DeLuca GC, Palace J. Age-related small vessel
disease: a potential contributor to neurodegeneration in multiple
sclerosis. Brain Pathol 2017; 27: 707–22.
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